Dissolution improvement of simvastatin by surface solid dispersion technology

Dissolution Technologies

Volumn 17, Issue 2, 2010, Pages 27-34

  Rao, Monica ^a   Mandage, Yogesh ^a   Thanki, Kaushik ^a   Bhise, Sucheta ^a  

^a AISSMS COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CROSCARMELLOSE SODIUM; DRUG CARRIER; SIMVASTATIN; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTESTINE FLUID; MALE; MOLECULAR INTERACTION; NONHUMAN; PH; RAT; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SURFACE PROPERTY; X RAY DIFFRACTION;

EID: 77954684495     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT170210P27     Document Type: Article

References (23)

1. Modi, P.; Tayade, H. K. A comparative solubility enhancement profile of valdecoxib with different solubilization approaches. Ind. J. Pharm. Sci. 2007, 69 (2), 274-278.
2. Pinnamaneni, N. G.; Das, N. G.; Das, S. K. Formulation approaches for orally administered poorly soluble drugs. Pharmazie 2002, 57 (5), 291-300.
3. Carlota, O.; Rangel, Y.; Adalberto, P.; Leoberto, C. T. Micellar solubilization of drugs. J. Pharm. Pharm. Sci. 2005, 8 (2), 147-163.
4. Nokhodchi, A.; Javadzadeh, Y.; Reza, M.; Barzega, J. M. The effect of type and concentration of vehicles on the dissolution rates of a poorly water soluble drug indomethacin from liquisolid compacts. J. Pharm. Pharm. Sci. 2005, 8 (1), 18-25.
5. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50 (1), 47-60.
6. Chiou, W. L.; Rigelman, S. Pharmaceutical application of solid dispersion system. J. Pharm. Sci. 1971, 60 (9), 1281-1302.
7. Serajuddin, A. Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs. J. Pharm. Sci. 1999, 88 (10), 1058-1066.
8. Craig, D. Q. M. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 2002, 231 (2), 131-144.
9. Cassidy, O. E.; Rouchotas, C. Comparison of surface modification and solid dispersion techniques for drug dissolution. Int. J. Pharm. 2000, 195 (2), 1-6.
10. Kang, B. K.; Lee, J. S.; Chon, S. K.; Jeong, S. Y.; Yuk, S. H.; Khang, G.; Lee, B. H.; Cho, S. H. Development of self- microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 2004, 274 (1-2), 65-73.
11. Ambike, A. A.; Mahadik, K. R.; Paradkar, A. Spray-Dried Amorphous Solid Dispersions of Simvastatin, a Low Tg Drug; In Vitro and In Vivo Evaluations. Pharm. Res. 2005, 22 (6), 990-998.
12. Cheng, H.; Sutton, S. C.; Pipikin, J. D.; Zentner, G. M.; Rogers, J. D.; Schwartz, J. I.; Mitchel, Y. B.; Grasing, K.; Schwartz, M. S.; Amin, R. D.; Liu, L.; Ebel, D. L.; Coulter, A.; Engle, K.; McClelland, G. A.; Lui, C. Y.; Rork, G. S. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor in dogs and humans. Pharm. Res. 1993, 10 (11), 683-1687.
13. McClelland, C. A.; Stubbs, R. J.; Fix, J. A.; Pogany, S. A.; Zentner, G.M. Enhancement of 3-hydroxy-3- methylglutaryl-coenzyme A (HMGCoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharm. Res. 1991, 8 (7), 873-876.
14. Dixit, R. P.; Nagarsenker, M. S. In vitro and in vivo advantage of celecoxib surface solid dispersion and dosage form development. Ind. J. Pharm. Sci. 2007, 69 (3), 370-377.
15. Cilurzo, F.; Minghetti, P.; Casiraghi, A. M. Characterization of nifedipine solid dispersions. Int. J. Pharm. 2002, 242 (1-2), 313-317.
16. Srinivas, M.; Parambil, A.; Krishnan, M.; Achuta, N. U. Enhancement of dissolution rate and bioavailability of aceclofenac: A chitosan-based solvent change approach. Int. J. Pharm. 2008, 350 (1-2), 279-290.
17. Kostwicz, E. S.; Brauns, U.; Becker, R.; Dressman, J. B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 2002, 19 (3), 345-349.
18. Margareth, M. Dissolution Media Simulating Fasted and Fed States. Dissolution Technol. 2004, 11 (2), 16.
19. Marija, T. G.; John, M.; Hilfinger, G. L. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 2007, 25 (7), 1591-1600.
20. Patel, A. R.; Vavia, P. R. Preparation and in vivo evalua- tion of SMEDDS self- microemulsifying drug delivery system containing fenofibrate. AAPS J. 2007, 9 (3), E344-E352.
21. Zlatkis, A.; Zak, B.; Boyle, A. J. New method for direct determination of serum cholesterol. J. Lab. Clin. Med. 1953, 41, 486-492.
22. United States Pharmacopeia and National Formulary USP 30-NF 25. The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2007; pp 3179-3180.
23. Margulis-Goshen, K.; Magdassi, S. Formation of simvastatin nanoparticles from microemulsion. Nanomed.-Nanotechnol. 2009, 5 (3), 274-281.